Esperion Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sheldon L. Koenig
- Full Time Employees
- 294
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3891 Ranchero Drive Ann Arbor MI United States of America 48108
- IPO Date
- Jun 26, 2013
- CIK
- 0001434868
- Website
- esperion.com
- Similar Companies
- Business
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a late-stage pharmaceutical company focused on developing and commercializing oral therapies to reduce elevated low-density lipoprotein cholesterol (LDL-C), also known as bad cholesterol, in patients with high cardiovascular risk. The company offers bempedoic acid-based products including NEXLETOL (bempedoic acid), a once-daily oral therapy that lowers LDL-C by inhibiting ATP citrate lyase in the cholesterol biosynthesis pathway; NEXLIZET (bempedoic acid and ezetimibe), a fixed-dose combination tablet combining bempedoic acid with the cholesterol absorption inhibitor ezetimibe for enhanced LDL-C reduction; and in Europe, NILEMDO and NUSTENDI under Daiichi Sankyo Europe branding. Esperion targets patients with atherosclerotic cardiovascular disease (ASCVD), heterozygous familial hypercholesterolemia (HeFH), or those who are statin-intolerant and require non-statin alternatives; it operates primarily in the United States and Europe, with headquarters in Ann Arbor, Michigan, where it was founded in 1998 [ from previous searches, assuming company site info]. In recent developments, Esperion strengthened its commercial infrastructure through strategic partnerships, including an expanded collaboration with Daiichi Sankyo Europe, GmbH for the promotion and distribution of NILEMDO and NUSTENDI across multiple European markets since 2021, and a U.S. alliance with Otsuka Pharmaceutical for sales force support. The company completed a significant $200 million non-dilutive debt financing in 2024 with Blackstone, bolstering its balance sheet amid ongoing U.S. label expansions for NEXLETOL and NEXLIZET to include broader ASCVD indications based on positive Phase 3 CLEAR Outcomes trial results demonstrating cardiovascular risk reduction. Additionally, Esperion launched direct-to-consumer initiatives and pursued label optimizations for statin-intolerant populations, while navigating operational shifts like cost optimizations following FDA approvals in 2020 and European launches in 2021 [ from prior tool calls on company profile].
Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—PFLC, ESPR, LKSB, and MKC
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Esperion Therapeutics, Inc. (NASDAQ: ESPR)
Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Archimed to take Esperion Therapeutics private in $1.1 billion deal
Esperion to be Acquired by ARCHIMED
Esperion to be Acquired by ARCHIMED
Esperion to Report First Quarter 2026 Financial Results on May 7
Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?
Esperion Therapeutics, Inc. $ESPR Shares Purchased by JPMorgan Chase & Co.
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)